Neurocrine Biosciences, which looked like it was stuck perpetual retrenchment-mode, just pulled off its second big deal in two days. Yesterday, the San Diego biotech agreed to grant German drug maker... Read more »
A spate of financings dominated the headlines in the past week. We’ve got it summarized for you here.
—Brain Cells’ experimental antidepressant was no better than placebo in a mid-stage... Read more »
Abbott Laboratories will pay Neurocrine Biosciences (NASDAQ:NBIX) of San Diego up to $575 million for exclusive worldwide rights to develop and commercialize Neurocrine’s experimental oral drug for endometriosis, a painful... Read more »
The pace of life sciences news slowed in the past week, but we know from experience the lull is temporary. You can catch up on the headlines here.
—A raft of... Read more »
[Updated 6/11/10 12:05 am. See below.] The cost of getting your genome sequenced continues to drop. San Diego’s Illumina (NASDAQ: ILMN) has lowered the cost of its individual... Read more »
Gen-Probe (NASDAQ: GPRO) appears to be on the right track with its experimental prostate cancer test, judging from a raft of recent clinical studies in men being screened for prostate... Read more »
Pathway Genomics’ plan to take genetic testing to the people continues to go badly awry.
A House panel disclosed yesterday that it is investigating personal genetic tests sold over the Internet... Read more »
The sector was firing on all burners in the past week with fresh developments in devices, drug development, wireless health, and weight loss (just ask Larry Smarr). You can catch all... Read more »
Sequenom can cross off another item on its long to-do list. The San Diego-based developer of diagnostic tests is announcing today that it has raised $51.6 million in a private placement... Read more »
As representatives of the emerging mobile health industry convene for their annual summit today in La Jolla, it seemed both timely and appropriate to revisit San Diego-based Sotera Wireless. The company,... Read more »
San Diego-based Cytori Therapeutics (NASDAQ: CYTX) is announcing encouraging results this morning from two small, placebo-controlled studies of its fat-derived regenerative cell therapy in cardiac patients. The double-blind studies, which... Read more »
We saw a spate of deal-making in the past week. Those developments and more are summarized for you here.
—Avalon Ventures, one of the few San Diego venture capital... Read more »
San Diego’s Cibus Global is uniting with Canada’s flax growers to develop a crop strain resistant to glyphosate, the active ingredient in the widely used weed killer Roundup. Flax, also known... Read more »
Progress on the drug development front dominated the headlines in the past week, although one company, Phenomix, also had some bad news. Get those details and more here.
—Phenomix announced... Read more »
As swine flu raced through colleges and communities last summer and fall, at least five San Diego companies with flu-related products or research programs saw their share prices surge. Investors were... Read more »
We heard in the past week from key experts who shared their views on the funding climate and the potential of emerging computational technologies. Our recap follows.
—Histogen said its... Read more »
San Diego’s role in computer analytics dates back to at least 1969, with the founding of Science Applications Inc., now SAIC, which used computer models to predict the effects of... Read more »
One notion that emerged at Xconomy’s event in San Diego last week was that biomedical informatics might have a promising role to play in the region’s economic future. There is no... Read more »
The integration of information technology and life sciences is well underway in San Diego, judging from the past week’s headlines. We’ve summarized it all here.
—Illumina (NASDAQ: ILMN) CEO Jay... Read more »
Experts agree that electronic medical records can lower costs and improve care. Yet just 10 percent of U.S. hospitals keep any computerized records, according to a survey in the New England... Read more »